Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Moderate symptom-based exacerbations as predictors of severe claims-based exacerbations in asthma.

Lane SJ, Petersen H, Seltzer JM, Blanchette CM, Navaratnam P, Allen-Ramey F, Fuhlbrigge A.

J Asthma. 2013 Aug;50(6):642-8. doi: 10.3109/02770903.2013.787624. Epub 2013 May 7.

PMID:
23514102
2.

Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.

Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA.

Int J Chron Obstruct Pulmon Dis. 2012;7:757-64. doi: 10.2147/COPD.S36997. Epub 2012 Nov 1.

3.

Uncontrolled asthma in a commercially insured population from 2002 to 2007: trends, predictors, and costs.

Sawicki GS, Vilk Y, Schatz M, Kleinman K, Abrams A, Madden J.

J Asthma. 2010 Jun;47(5):574-80. doi: 10.3109/02770901003792841.

PMID:
20560831
4.
5.

[Cost and management of asthma exacerbations in Spanish hospitals (COAX study in hospital services)].

Borderías Clau L, Zabaleta Murguionda M, Riesco Miranda JA, Pellicer Ciscar C, Hernández Hernández JR, Carrillo Díaz T, Lumbreras García G.

Arch Bronconeumol. 2005 Jun;41(6):313-21. Spanish.

6.

Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis.

Abudagga A, Sun SX, Tan H, Solem CT.

Int J Chron Obstruct Pulmon Dis. 2013;8:175-85. doi: 10.2147/COPD.S40437. Epub 2013 Apr 9.

7.

Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.

Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

Ann Allergy Asthma Immunol. 2012 Jul;109(1):59-64. doi: 10.1016/j.anai.2012.04.015. Epub 2012 May 12.

PMID:
22727159
8.

Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma.

Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K.

J Allergy Clin Immunol. 2012 May;129(5):1229-35. doi: 10.1016/j.jaci.2012.01.039. Epub 2012 Feb 11.

PMID:
22326484
9.

Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a Medicare-eligible population.

Stanford RH, Blanchette CM, Roberts MH, Petersen H, Fuhlbrigge AL.

Am J Geriatr Pharmacother. 2012 Dec;10(6):343-51. doi: 10.1016/j.amjopharm.2012.09.005. Epub 2012 Oct 17.

PMID:
23083688
10.

Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone.

Gerhardsson de Verdier M, Andersson M, Kern DM, Zhou S, Tunceli O.

Value Health. 2015 Sep;18(6):759-66. doi: 10.1016/j.jval.2015.04.010. Epub 2015 Jun 22.

11.

Association between episodes of upper respiratory infection and exacerbations in adult patients with asthma.

Tomita K, Sano H, Iwanaga T, Ishihara K, Ichinose M, Kawase I, Kimura H, Hirata K, Fujimura M, Mishima M, Tohda Y.

J Asthma. 2012 Apr;49(3):253-9. doi: 10.3109/02770903.2012.661009. Epub 2012 Feb 29.

PMID:
22376075
12.

Ratio of controller to total asthma medications: determinants of the measure.

Broder MS, Gutierrez B, Chang E, Meddis D, Schatz M.

Am J Manag Care. 2010 Mar;16(3):170-8.

13.

Asthma outcomes: exacerbations.

Fuhlbrigge A, Peden D, Apter AJ, Boushey HA, Camargo CA Jr, Gern J, Heymann PW, Martinez FD, Mauger D, Teague WG, Blaisdell C.

J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S34-48. doi: 10.1016/j.jaci.2011.12.983. Review.

14.

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.

Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, Woolacott N.

Pharmacoeconomics. 2012 Nov 1;30(11):991-1004. doi: 10.2165/11597160-000000000-00000. Review.

PMID:
22950547
15.

Asthma exacerbation rates in adults are unchanged over a 5-year period despite high-intensity therapy.

Schatz M, Meckley LM, Kim M, Stockwell BT, Castro M.

J Allergy Clin Immunol Pract. 2014 Sep-Oct;2(5):570-4.e1. doi: 10.1016/j.jaip.2014.05.002. Epub 2014 Jul 3.

PMID:
25213050
16.

Subacute lack of asthma control and acute asthma exacerbation history as predictors of subsequent acute asthma exacerbations: evidence from managed care data.

O'Connor RD, Bleecker ER, Long A, Tashkin D, Peters S, Klingman D, Gutierrez B.

J Asthma. 2010 May;47(4):422-8. doi: 10.3109/02770901003605332.

PMID:
20528597
17.

A retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting beta-agonists for asthma maintenance treatment in Germany.

Aballéa S, Cure S, Vogelmeier C, Wirén A.

Int J Clin Pract. 2008 Dec;62(12):1870-9. doi: 10.1111/j.1742-1241.2008.01895.x. Epub 2008 Sep 17.

19.

A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain.

Quirce S, Barcina C, Plaza V, Calvo E, Muñoz M, Ampudia R, Capel M.

J Asthma. 2011 Oct;48(8):839-47. doi: 10.3109/02770903.2011.611954. Erratum in: J Asthma. 2012 Aug;49(6):663.

PMID:
21942354
20.

Relationship between short-acting β2-adrenergic agonist use and healthcare costs.

Silver HS, Blanchette CM, Kamble S, Petersen H, Letter MA, Meddis D, Gutierrez B.

Am J Manag Care. 2011 Jan;17(1):19-27.

Items per page

Supplemental Content

Write to the Help Desk